CA2684242C - Somatic cell reprogramming - Google Patents

Somatic cell reprogramming Download PDF

Info

Publication number
CA2684242C
CA2684242C CA2684242A CA2684242A CA2684242C CA 2684242 C CA2684242 C CA 2684242C CA 2684242 A CA2684242 A CA 2684242A CA 2684242 A CA2684242 A CA 2684242A CA 2684242 C CA2684242 C CA 2684242C
Authority
CA
Canada
Prior art keywords
cells
cell
potency
pluripotent
determining factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2684242A
Other languages
English (en)
French (fr)
Other versions
CA2684242A1 (en
Inventor
Junying Yu
James Thomson
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39708430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2684242(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of CA2684242A1 publication Critical patent/CA2684242A1/en
Application granted granted Critical
Publication of CA2684242C publication Critical patent/CA2684242C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2684242A 2007-03-23 2008-03-21 Somatic cell reprogramming Active CA2684242C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US91968707P 2007-03-23 2007-03-23
US60/919,687 2007-03-23
US97498007P 2007-09-25 2007-09-25
US60/974,980 2007-09-25
US98905807P 2007-11-19 2007-11-19
US60/989,058 2007-11-19
PCT/US2008/057924 WO2008118820A2 (en) 2007-03-23 2008-03-21 Somatic cell reprogramming

Publications (2)

Publication Number Publication Date
CA2684242A1 CA2684242A1 (en) 2008-10-02
CA2684242C true CA2684242C (en) 2019-11-12

Family

ID=39708430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2684242A Active CA2684242C (en) 2007-03-23 2008-03-21 Somatic cell reprogramming

Country Status (11)

Country Link
US (7) US8440461B2 (enExample)
EP (2) EP3399025B1 (enExample)
JP (6) JP5813321B2 (enExample)
KR (1) KR101516833B1 (enExample)
CN (1) CN101743306A (enExample)
AU (1) AU2008231020B2 (enExample)
CA (1) CA2684242C (enExample)
DK (1) DK3399025T3 (enExample)
IL (1) IL200982A (enExample)
SG (2) SG193652A1 (enExample)
WO (1) WO2008118820A2 (enExample)

Families Citing this family (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
US8034613B2 (en) 2005-06-01 2011-10-11 Wisconsin Alumni Research Foundation Multipotent lymphohematopoietic progenitor cells
GB2440494B (en) * 2005-06-01 2010-07-28 Wisconsin Alumni Res Found Method of forming dendritic from embryonic stem cells
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
CN101864392B (zh) 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
US8129187B2 (en) 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
GB2449042B (en) * 2006-02-09 2010-07-07 Wisconsin Alumni Res Found Erythroid cells producing adult-type b-hemoglobin generated from human embryonic stem cells
EP3399025B1 (en) 2007-03-23 2025-05-07 Wisconsin Alumni Research Foundation Somatic cell reprogramming
EP2626416A3 (en) 2007-04-07 2013-12-18 The Whitehead Institute for Biomedical Research Reprogramming of somatic cells
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
US20110236971A2 (en) * 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
AU2008297024B2 (en) * 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
US9683232B2 (en) 2007-12-10 2017-06-20 Kyoto University Efficient method for nuclear reprogramming
JP5558097B2 (ja) * 2007-12-10 2014-07-23 国立大学法人京都大学 効率的な核初期化方法
CN101855350B (zh) 2008-05-02 2014-12-31 国立大学法人京都大学 核重编程序方法
US20090280096A1 (en) * 2008-05-09 2009-11-12 Atsushi Kubo Pancreatic endocrine progenitor cells derived from pluripotent stem cells
CA2726990C (en) 2008-06-04 2020-09-08 Cellular Dynamics International, Inc. Methods for the production of ips cells using extra-chromosomal vectors
US9497943B2 (en) 2008-06-13 2016-11-22 Whitehead Institute For Biomedical Research Nucleic acid constructs encoding reprogramming factors linked by self-cleaving peptides
KR101606943B1 (ko) 2008-06-27 2016-03-28 고쿠리츠 다이가쿠 호진 교토 다이가쿠 유도된 다능성 줄기 세포의 효율적인 확립 방법
CN101848994A (zh) 2008-07-30 2010-09-29 国立大学法人京都大学 有效建立诱导的多能干细胞的方法
JP2012500005A (ja) * 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
WO2010033906A2 (en) * 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
WO2010042800A1 (en) * 2008-10-10 2010-04-15 Nevada Cancer Institute Methods of reprogramming somatic cells and methods of use for such cells
CN102239249A (zh) * 2008-10-24 2011-11-09 威斯康星校友研究基金会 通过非病毒重编程获得的多潜能干细胞
WO2010050626A1 (en) * 2008-10-30 2010-05-06 Kyoto University Method for producing induced pluripotent stem cells
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
EP2376626A4 (en) * 2008-12-13 2012-10-17 Dna Microarray MICRO-ENVIRONMENTAL NICHE ASSAY FOR SCREENING OF INDUCED PLURIPOTENT STEM CELLS (CIPS)
US20110300627A1 (en) * 2009-01-20 2011-12-08 Sing George L Dedifferentiation and reprogramming of cells
EP2398897B1 (en) 2009-02-20 2017-06-28 Cellular Dynamics International, Inc. Methods and compositions for the differentiation of stem cells
CN102388136B (zh) 2009-02-27 2014-10-01 国立大学法人京都大学 新颖的核重编程序物质
ES2900277T3 (es) * 2009-03-20 2022-03-16 Mesoblast Inc Producción de células pluripotentes reprogramadas
ES2849181T3 (es) 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
WO2010137348A1 (en) 2009-05-29 2010-12-02 Keio University Method for selecting clone of induced pluripotent stem cells
CA2952805C (en) 2009-06-05 2021-06-01 Cellular Dynamics International, Inc. Reprogramming t cells and hematopoietic cells
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
JP5645197B2 (ja) * 2009-06-23 2014-12-24 学校法人日本大学 幹細胞の未分化状態を維持する新規方法
WO2011016588A1 (en) 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
US8709805B2 (en) 2009-08-07 2014-04-29 Kyoto University Canine iPS cells and method of producing same
WO2011021706A1 (ja) 2009-08-19 2011-02-24 国立大学法人東北大学 角膜移植用シート
US8993329B2 (en) 2009-09-24 2015-03-31 Kyoto University Method of efficiently establishing induced pluripotent stem cells
GB2474492B (en) * 2009-10-19 2014-05-21 Tristem Trading Cyprus Ltd Treatment using reprogrammed mature adult cells
EP2494032A4 (en) * 2009-10-29 2013-06-05 Univ Mcmaster GENERATION OF INDUCED PLURIPOTENTER STEM CELLS AND FIBROBLAST PRECURSOR CELLS
CN102695790A (zh) * 2009-10-29 2012-09-26 詹森生物科技公司 多能干细胞
JP5898086B2 (ja) 2009-11-04 2016-04-06 セルラー ダイナミクス インターナショナル， インコーポレイテッド 化学物質を用いるエピソームリプログラミング
JPWO2011071118A1 (ja) 2009-12-09 2013-04-22 国立大学法人京都大学 ニトロビンを含む多能性幹細胞の心筋細胞への分化促進剤
EP2512514B1 (en) 2009-12-14 2014-11-05 Kyoto University Screening method for identifying compounds for treating amyotrophic lateral sclerosis
EP2526189B1 (en) 2010-01-22 2016-10-12 Kyoto University Method for improving induced pluripotent stem cell generation efficiency
CA2789749C (en) 2010-02-16 2018-09-04 Kyoto University Method of efficiently establishing induced pluripotent stem cells
CN102190731B (zh) * 2010-03-09 2016-01-27 中国科学院上海生命科学研究院 用人工转录因子诱导产生多能干细胞
CA2792696C (en) 2010-03-17 2020-01-07 Association Institut De Myologie Modified u7 snrnas for treatment of neuromuscular diseases
WO2011118655A1 (ja) * 2010-03-23 2011-09-29 オリンパス株式会社 幹細胞の分化状態をモニタリングする方法
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
CN102892879B (zh) * 2010-05-13 2016-10-12 加州大学董事会 用于诱导人类多能干细胞的方法和组合物
WO2011159684A2 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. Generation of induced pluripotent stem cells from small volumes of peripheral blood
EP2582795B1 (en) 2010-06-15 2017-04-12 Kyoto University Method for selecting human induced pluripotent stem cells
US9938496B2 (en) 2010-08-13 2018-04-10 Kyoto University Method of inducing differentiation from pluripotent stem cells to germ cells
CN103168236B (zh) 2010-08-23 2016-01-20 哈佛大学管理委员会 用于膜电位测定的光遗传学探针
WO2012026491A1 (ja) 2010-08-26 2012-03-01 国立大学法人京都大学 多能性幹細胞の心筋分化促進剤
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
EP2611437B1 (en) 2010-09-02 2017-03-29 Kyoto University Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis
JP5794588B2 (ja) 2010-09-14 2015-10-14 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
CA2812194C (en) 2010-09-17 2022-12-13 President And Fellows Of Harvard College Functional genomics assay for characterizing pluripotent stem cell utility and safety
US9732128B2 (en) 2010-10-22 2017-08-15 Biotime, Inc. Methods of modifying transcriptional regulatory networks in stem cells
US9506039B2 (en) 2010-12-03 2016-11-29 Kyoto University Efficient method for establishing induced pluripotent stem cells
JP2014506453A (ja) 2011-01-19 2014-03-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 生得的多能性体細胞
WO2012098260A1 (en) 2011-01-21 2012-07-26 Axiogenesis Ag A non-viral system for the generation of induced pluripotent stem (ips) cells
WO2012137970A1 (ja) 2011-04-08 2012-10-11 国立大学法人大阪大学 改変ラミニンおよびその利用
WO2012141181A1 (ja) * 2011-04-11 2012-10-18 国立大学法人京都大学 核初期化物質
US9133266B2 (en) 2011-05-06 2015-09-15 Wisconsin Alumni Research Foundation Vitronectin-derived cell culture substrate and uses thereof
CN103703130A (zh) 2011-07-25 2014-04-02 国立大学法人京都大学 筛选诱导的多能干细胞的方法
WO2013028702A1 (en) * 2011-08-22 2013-02-28 Mayo Foundation For Medical Education And Research Methods and materials for obtaining induced pluripotent stem cells
WO2013028684A1 (en) 2011-08-23 2013-02-28 Wisconsin Alumni Research Foundation Angiohematopoietic progenitor cells
US20130274184A1 (en) * 2011-10-11 2013-10-17 The Trustees Of Columbia University In The City Of New York Er stress relievers in beta cell protection
WO2013058403A1 (ja) 2011-10-21 2013-04-25 国立大学法人京都大学 層流による多能性維持単一分散細胞培養法
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US20140329317A1 (en) 2011-11-25 2014-11-06 Kyoto University Method for culturing pluripotent stem cell
US10238755B2 (en) 2011-11-30 2019-03-26 The Wistar Institute Of Anatomy And Biology Methods and compositions for regulation of cell aging, carcinogenesis and reprogramming
US8450107B1 (en) 2011-11-30 2013-05-28 The Broad Institute Inc. Nucleotide-specific recognition sequences for designer TAL effectors
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US8497124B2 (en) 2011-12-05 2013-07-30 Factor Bioscience Inc. Methods and products for reprogramming cells to a less differentiated state
RU2691027C2 (ru) 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
US8772460B2 (en) 2011-12-16 2014-07-08 Wisconsin Alumni Research Foundation Thermostable FGF-2 mutant having enhanced stability
WO2013111875A1 (ja) 2012-01-27 2013-08-01 国立大学法人京都大学 多能性幹細胞の心筋分化誘導法
AU2013264708B2 (en) 2012-05-23 2019-03-07 Kyoto University Highly efficient method for establishing artificial pluripotent stem cell
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
US9175263B2 (en) 2012-08-22 2015-11-03 Biotime, Inc. Methods and compositions for targeting progenitor cell lines
WO2014057997A1 (ja) 2012-10-09 2014-04-17 Hayashi Nakanobu 初期化ペプチド及びその用途
SG11201503167XA (en) 2012-10-23 2015-05-28 Univ Kyoto Method of efficiently establishing induced pluripotent stem cells
EP2914728B1 (en) 2012-11-01 2020-07-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
WO2014124087A1 (en) 2013-02-06 2014-08-14 University Of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US20160002599A1 (en) 2013-02-08 2016-01-07 Kyoto University Production methods for megakaryocytes and platelets
EP2966163B1 (en) 2013-03-06 2018-01-17 Kyoto University Culture system for pluripotent stem cells and method for subculturing pluripotent stem cells
US10196609B2 (en) 2013-03-08 2019-02-05 Kyoto University Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor
SG11201507275TA (en) 2013-03-13 2015-10-29 Wisconsin Alumni Res Found Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
US8859286B2 (en) 2013-03-14 2014-10-14 Viacyte, Inc. In vitro differentiation of pluripotent stem cells to pancreatic endoderm cells (PEC) and endocrine cells
US10519421B2 (en) 2013-03-21 2019-12-31 Kyoto University Induction of motor neurons from pluripotent stem cells
US10072242B2 (en) 2013-03-25 2018-09-11 Foundation For Biomedical Research And Innovation At Kobe Cell sorting method
CA2909230C (en) 2013-04-12 2021-06-15 Kyoto University Method for inducing alveolar epithelial progenitor cells
JP6429280B2 (ja) 2013-05-14 2018-11-28 国立大学法人京都大学 効率的な心筋細胞の誘導方法
KR101870174B1 (ko) 2013-05-31 2018-06-22 아이하트 재팬 가부시키가이샤 하이드로겔을 포함하는 적층화된 세포 시트
CA2914615C (en) 2013-06-05 2023-10-17 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
JP6697380B2 (ja) 2013-06-10 2020-05-20 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 多能性幹細胞の有用性および安全性を特徴付けるための初期発生ゲノムアッセイ
CA2915085C (en) 2013-06-11 2021-04-27 Kyoto University Method for producing renal progenitor cells and drug comprising the same
WO2015006725A2 (en) 2013-07-12 2015-01-15 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells from normal human mammary epithelial cells
WO2015020113A1 (ja) 2013-08-07 2015-02-12 国立大学法人京都大学 膵ホルモン産生細胞の製造法
CN105849255A (zh) 2013-09-05 2016-08-10 国立大学法人京都大学 新的产多巴胺神经前体细胞诱导方法
WO2015037535A1 (ja) 2013-09-12 2015-03-19 株式会社カネカ 人工多能性幹細胞の分化誘導方法及び選別方法
EP3045451B1 (en) 2013-09-13 2018-03-28 Kyoto University Compound promoting differentiation of pluripotent stem cells into cardiomyocytes
KR102219743B1 (ko) 2013-11-01 2021-02-23 고쿠리츠 다이가쿠 호진 교토 다이가쿠 신규 연골 세포 유도 방법
WO2015069736A1 (en) 2013-11-08 2015-05-14 The Mclean Hospital Corporation METHODS FOR EFFICIENT GENERATION OF GABAergic INTERNEURONS FROM PLURIPOTENT STEM CELLS
US11377639B2 (en) 2013-11-15 2022-07-05 Wisconsin Alumni Research Foundation Lineage reprogramming to induced cardiac progenitor cells (iCPC) by defined factors
BR112016012129A8 (pt) 2013-12-11 2020-05-12 Pfizer Ltd métodos para produção, expansão e purificação de células epiteliais do pigmento da retina, composição farmacêutica e uso das células
CN105940110A (zh) 2014-01-31 2016-09-14 菲克特生物科学股份有限公司 用于核酸产生和递送的方法和产品
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
WO2015182765A1 (ja) 2014-05-30 2015-12-03 国立大学法人京都大学 低分子化合物を用いた多能性幹細胞の心筋分化誘導法
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
JP7012432B2 (ja) 2014-07-14 2022-01-28 中外製薬株式会社 タンパク質のエピトープを同定するための方法
SG10201900323SA (en) 2014-07-18 2019-02-27 Univ Kyoto Method for inducing t cells for cell-based immunotherapy from pluripotent stem cells
CN120924475A (zh) 2014-09-18 2025-11-11 北卡罗来纳大学 哺乳动物肺球体和肺球体细胞及其应用
WO2016054591A1 (en) 2014-10-03 2016-04-07 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
EP3204502B1 (en) 2014-10-06 2021-04-21 Memorial Sloan-Kettering Cancer Center Method to reduce oncogenic potential of induced pluripotent stem cells from aged donors
JP6865167B2 (ja) 2014-12-17 2021-04-28 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター
ES2784264T3 (es) 2014-12-17 2020-09-23 Fundacion Para La Investig Medica Aplicada Construcciones de ácido nucleico y vectores de terapia génica para su uso en el tratamiento de la enfermedad de Wilson y otras afecciones
WO2016104717A1 (ja) 2014-12-26 2016-06-30 国立大学法人京都大学 肝細胞誘導方法
SG11201705820UA (en) 2015-01-16 2017-08-30 Nat Inst Advanced Ind Science & Tech Gene expression system using stealthy rna, and gene introduction/expression vector including said rna
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3081638A1 (en) 2015-04-16 2016-10-19 Kyoto University Method for producing pseudo-islets
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
CA2997763A1 (en) 2015-09-08 2017-03-16 Cellular Dynamics International, Inc. Macs-based purification of stem cell-derived retinal pigment epithelium
KR102781602B1 (ko) 2015-09-08 2025-03-18 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 임상 등급 망막 색소 상피 세포의 재현성 있는 분화 방법
ES2862676T3 (es) 2015-10-20 2021-10-07 Fujifilm Cellular Dynamics Inc Producción de células precursoras hematopoyéticas multilinaje mediante programación genética
US10801041B2 (en) 2015-11-18 2020-10-13 Orbis Health Solutions, Llc T7 alpha viral vector system
BR112018010639A2 (pt) * 2015-11-24 2019-01-22 Glaxosmithkline Ip Dev Ltd método de transfecção transitória para produção retroviral.
CN108779435B (zh) 2015-12-07 2022-05-03 再生疗法有限公司 用于重新衍生不同的多能干细胞衍生的褐色脂肪细胞的方法
US11253551B2 (en) 2016-01-11 2022-02-22 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
CN109153973A (zh) 2016-03-18 2019-01-04 国立大学法人京都大学 用于冷冻多能干细胞来源心肌细胞的聚集体的方法
WO2017179720A1 (ja) 2016-04-15 2017-10-19 国立大学法人京都大学 Ｃｄ８陽性ｔ細胞を誘導する方法
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法
EP3455346A1 (en) 2016-05-12 2019-03-20 Erasmus University Medical Center Rotterdam A method for culturing myogenic cells, cultures obtained therefrom, screening methods, and cell culture medium
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
CN105861447B (zh) * 2016-06-13 2017-12-19 广州市搏克生物技术有限公司 一种非病毒iPSCs诱导组合物及其试剂盒
US10221395B2 (en) 2016-06-16 2019-03-05 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
US11572545B2 (en) 2016-06-16 2023-02-07 Cedars-Sinai Medical Center Efficient method for reprogramming blood to induced pluripotent stem cells
CN105936889B (zh) * 2016-06-24 2019-10-18 肇庆大华农生物药品有限公司 一种ad293球形细胞团的培养方法
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
EP3515459A4 (en) 2016-09-20 2020-08-05 Cedars-Sinai Medical Center CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS
EP3523422B1 (en) 2016-10-05 2024-12-25 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
EP3564385A4 (en) 2016-12-27 2020-08-12 Sumitomo Chemical Company, Limited ASSESSMENT AND SELECTION PROCEDURE FOR INDUCED PLURIPOTENT STEM CELLS, AND PROCESS FOR MANUFACTURING INDUCED PLURIPOTENT STEM CELLS
US12006512B2 (en) 2017-01-20 2024-06-11 Kyoto University Method for producing CD8alpha+beta+ cytotoxic t cells
EP3575392A4 (en) 2017-01-26 2020-08-26 Osaka University MEDIUM INTENDED TO INDUCE DIFFERENTIATION OF STEM CELLS INTO MESODERMAL CELLS AND PROCESS INTENDED TO PRODUCE MESODERMAL CELLS
WO2018159805A1 (ja) 2017-03-03 2018-09-07 国立大学法人京都大学 膵前駆細胞の製造方法
JP7171055B2 (ja) 2017-03-14 2022-11-15 国立大学法人京都大学 多能性幹細胞からヘルパーｔ細胞を製造する方法
AU2018254442B2 (en) 2017-04-18 2024-03-28 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
CA3059910A1 (en) 2017-04-19 2018-10-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
JP7457505B2 (ja) 2017-05-10 2024-03-28 ユニバーシティー オブ ロチェスター 神経精神障害を処置する方法
EP3633026A4 (en) 2017-05-25 2021-03-10 Kyoto University METHOD FOR INDUCING THE DIFFERENTIATION OF A MESODERMAL INTERMEDIATE CELL TO A KIDNEY PRECURSOR CELL AND METHOD FOR INDUCING THE DIFFERENTIATION OF A PLURIPOTENT STEM CELL FROM A KIDNEY PRECURSOR CELL
US20200208093A1 (en) 2017-06-14 2020-07-02 Takeda Pharmaceutical Company Limited Cell-sealing device
WO2018235583A1 (ja) 2017-06-19 2018-12-27 公益財団法人神戸医療産業都市推進機構 多能性幹細胞の分化能の予測方法及びそのための試薬
JP6758631B2 (ja) 2017-06-19 2020-09-23 国立大学法人大阪大学 角膜内皮細胞マーカー及びその利用
US10760057B2 (en) 2017-07-06 2020-09-01 Wisconsin Alumni Research Foundation Human pluripotent stem cell-based screening for smooth muscle cell differentiation and disease
US11718829B2 (en) * 2017-07-28 2023-08-08 Breakthrough Tech Llc Methods and compositions for manufacturing extracellular matrix
NL2019517B1 (en) 2017-09-08 2019-03-19 Univ Erasmus Med Ct Rotterdam New therapy for Pompe disease
JP7140400B2 (ja) 2017-10-17 2022-09-21 国立大学法人京都大学 多能性幹細胞から人工神経筋接合部を得る方法
JP7401432B2 (ja) 2017-12-01 2023-12-19 エンコーデッド セラピューティクス， インコーポレイテッド 操作されたｄｎａ結合タンパク質
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
WO2019152549A1 (en) 2018-02-05 2019-08-08 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and y-rnas
CN111868235A (zh) 2018-03-19 2020-10-30 国立大学法人京都大学 水凝胶胶囊
TWI905079B (zh) 2018-04-23 2025-11-21 日商千紙鶴治療公司 增殖抑制劑
CA3103663A1 (en) 2018-06-18 2019-12-26 University Of Rochester Inhibition of re1-silencing transcription factor in the treatment of schizophrenia and other neuropsychiatric disorders
KR20210054502A (ko) 2018-06-21 2021-05-13 유니버시티 오브 로체스터 헌팅턴병을 치료하거나 이의 발병을 저해하는 방법
US12391739B2 (en) 2018-07-13 2025-08-19 Kyoto University Method for producing gamma delta T cells
EP3824912A4 (en) 2018-07-19 2022-04-20 Kyoto University PLATEFORM CARTILAGE DERIVED FROM PLURIPOTENTS STEM CELLS AND METHODS FOR PRODUCTION OF PLATEFORM CARTILAGE
JP7357369B2 (ja) 2018-07-23 2023-10-06 国立大学法人京都大学 新規腎前駆細胞マーカーおよびそれを利用した腎前駆細胞の濃縮方法
EP4455166A3 (en) 2018-08-10 2025-01-15 Kyoto University Method for producing cd3-positive cell
AU2019336221B2 (en) 2018-09-07 2025-05-15 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
CA3116098A1 (en) 2018-10-12 2020-04-16 Vivet Therapeutics Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3)
JP2022512930A (ja) 2018-11-07 2022-02-07 ヴィヴェ テラピューティクス 進行性家族性肝内胆汁鬱滞タイプ２（ｐｆｉｃ２）の治療のためのコドン最適化ａｂｃｂ１１導入遺伝子
EP3880809A4 (en) 2018-11-16 2023-01-11 Encoded Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF WILSON'S DISEASE
CN113573778B (zh) 2018-11-16 2025-05-13 拉帕治疗有限公司 使用诱导性调节性T（iTREG）细胞进行的ALS治疗
WO2020102715A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Method for t cell de-differentiation and resulting cells
AU2019386140A1 (en) 2018-11-28 2021-06-24 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en) 2018-11-29 2020-06-04 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
JP7016102B2 (ja) 2018-12-06 2022-02-04 キリンホールディングス株式会社 Ｔ細胞又はｎｋ細胞の製造方法、ｔ細胞又はｎｋ細胞の培養用培地、ｔ細胞又はｎｋ細胞の培養方法、未分化ｔ細胞の未分化状態を維持する方法及びｔ細胞又はｎｋ細胞の増殖促進剤
CA3122289A1 (en) 2018-12-11 2020-06-18 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
JP7224001B2 (ja) 2018-12-21 2023-02-17 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
WO2020138371A1 (ja) 2018-12-26 2020-07-02 キリンホールディングス株式会社 改変ｔｃｒ及びその製造方法
WO2020167822A2 (en) 2019-02-13 2020-08-20 University Of Rochester Gene networks that mediate remyelination of the human brain
US20220145255A1 (en) 2019-02-26 2022-05-12 Tohoku University Method for producing osteoblast cluster using ips cells
JP7700673B2 (ja) 2019-05-15 2025-07-01 味の素株式会社 神経堤細胞または角膜上皮細胞の純化方法
EP3974519A4 (en) 2019-05-20 2023-07-12 Ajinomoto Co., Inc. EXPANSION CULTURE METHOD FOR CARTILAGE OR BONE PRECURSOR CELLS
WO2020243651A1 (en) 2019-05-29 2020-12-03 Encoded Therapeutics, Inc. Compositions and methods for selective gene regulation
JP7699552B2 (ja) 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
US20230030814A1 (en) 2019-12-12 2023-02-02 National University Corporation Chiba University Freeze-Dried Preparations Comprising Megakaryocytes and Platelets
CN115427555A (zh) 2020-02-28 2022-12-02 武田药品工业株式会社 由多能干细胞产生自然杀伤细胞的方法
JPWO2021200901A1 (enExample) 2020-03-31 2021-10-07
EP4159846A4 (en) 2020-05-26 2024-08-14 Healios K.K. HYPOIMMUNOGENIC CELLS
EP3922431A1 (en) 2020-06-08 2021-12-15 Erasmus University Medical Center Rotterdam Method of manufacturing microdevices for lab-on-chip applications
EP4170020A4 (en) 2020-06-17 2025-01-22 Kyoto University IMMUNOCOMPETENT CELLS WITH CHIMERIC ANTIGEN RECEPTOR EXPRESSION
US20230256024A1 (en) 2020-07-13 2023-08-17 Kyoto University Skeletal muscle precursor cells and method for purifying same, composition for treating myogenic diseases, and method for producing cell group containing skeletal muscle precursor cells
EP4180514A4 (en) 2020-07-20 2024-09-04 Aichi Medical University COMPOSITION FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, MEDIUM FOR UNDIFFERENTIATED MAINTENANCE CULTURE OF PLURIPOTENT CELLS, METHOD FOR MAINTENANCE CULTURE IN UNDIFFERENTIATED STATE OF PLURIPOTENT CELLS, AND METHOD FOR PRODUCING PLURIPOTENT CELLS
US20230265456A1 (en) 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
WO2022039279A1 (ja) 2020-08-18 2022-02-24 国立大学法人京都大学 ヒト始原生殖細胞／ヒト始原生殖細胞様細胞の維持増幅方法
JP7808298B2 (ja) 2020-09-04 2026-01-29 Ｈｅａｒｔｓｅｅｄ株式会社 ｉＰＳ細胞の品質改善剤、ｉＰＳ細胞の製造方法、ｉＰＳ細胞、及びｉＰＳ細胞製造用組成物
WO2022069598A1 (en) 2020-09-29 2022-04-07 Genethon Enhancing utrophin expression in cell by inducing mutations within utrophin regulatory elements and therapeutic use thereof
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
CA3202411A1 (en) 2020-12-16 2022-06-23 Marc Guell Cargol Therapeutic lama2 payload for treatment of congenital muscular dystrophy
WO2022136616A1 (en) 2020-12-23 2022-06-30 Vivet Therapeutics Minimal bile acid inducible promoters for gene therapy
JPWO2022196714A1 (enExample) 2021-03-17 2022-09-22
US20220333074A1 (en) 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
CA3214045A1 (en) 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
EP4331673A4 (en) 2021-04-30 2025-06-25 Riken Cord-like aggregates of retinal apigment epithelial cells, device and method of manufacture for the production thereof, and therapeutic agent comprising said cord-like aggregates
JPWO2022255489A1 (enExample) 2021-06-04 2022-12-08
CA3222761A1 (en) 2021-06-10 2022-12-15 Ajinomoto Co., Inc. Method for producing mesenchymal stem cells
WO2022264033A1 (en) 2021-06-15 2022-12-22 Takeda Pharmaceutical Company Limited Method for producing natural killer cells from pluripotent stem cells
WO2023286832A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞の製造方法
WO2023286834A1 (ja) 2021-07-15 2023-01-19 アステラス製薬株式会社 血管内皮増殖因子（ｖｅｇｆ）高発現ペリサイト様細胞
EP4374914A4 (en) 2021-07-21 2025-07-16 Univ Kyoto PROCESS FOR PRODUCING RETINAL TISSUE
JPWO2023017848A1 (enExample) 2021-08-11 2023-02-16
EP4402249A1 (en) 2021-09-13 2024-07-24 Fujifilm Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
US20240400622A1 (en) 2021-09-23 2024-12-05 President And Fellows Of Harvard College Genetically encoded voltage indicators and uses thereof
WO2023053220A1 (ja) 2021-09-28 2023-04-06 公益財団法人京都大学ｉＰＳ細胞研究財団 多能性幹細胞の製造方法
WO2023069386A1 (en) * 2021-10-18 2023-04-27 Wisconsin Alumni Research Foundation Systems and methods for label-free tracking of human somatic cell reprogramming
CA3235105A1 (en) 2021-10-20 2023-04-27 Steven A. Goldman Humanized chimeras for the prospective assessment of glial cell addition or replacement therapy
WO2023069881A1 (en) 2021-10-20 2023-04-27 University Of Rochester Treatment with genetically modified cells, and genetically modified cells per se, with increased competitive advantage and/or decreased competitive disadvantage
AU2022368907A1 (en) 2021-10-20 2024-05-02 University Of Copenhagen Rejuvenation treatment of age-related white matter loss
US20230270818A1 (en) 2021-11-02 2023-08-31 University Of Rochester Tcf7l2 mediated remyelination in the brain
CN118265792A (zh) 2021-11-11 2024-06-28 希里欧斯株式会社 基因修饰多能干细胞、来自其的免疫活性细胞、它们的制造方法和它们的用途
EP4472648A1 (en) 2022-02-01 2024-12-11 University of Rochester Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods
EP4477746A4 (en) 2022-02-09 2026-02-18 Racthera Co Ltd METHOD FOR EVALUATING THE DIFFERENTIATION POTENTIAL OF CELLS IN A CULTURE BROTH IN THE DIFFERENCE OF MULTIPOTENTED STEM CELLS INTO NEURAL CELLS OF THE MENSCEPHAL FLOOR PLAQUE REGION
WO2023210713A1 (ja) 2022-04-27 2023-11-02 国立大学法人京都大学 心外膜細胞再生促進剤および心外膜細胞の再生促進方法
WO2023215455A1 (en) 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
WO2023240147A1 (en) 2022-06-08 2023-12-14 Century Therapeutics, Inc. Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof
US20250376727A1 (en) 2022-06-10 2025-12-11 Kyoto University Detection method and detection reagent for undifferentiated pluripotent stem cells
JPWO2024024551A1 (enExample) 2022-07-26 2024-02-01
US20240139256A1 (en) 2022-09-30 2024-05-02 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
CN120897992A (zh) 2023-01-23 2025-11-04 瑞克生乐有限公司 视网膜组织的生产方法
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
WO2024248023A1 (ja) 2023-05-29 2024-12-05 京都府公立大学法人 視交叉上核オルガノイドの製造方法
EP4722345A1 (en) 2023-05-29 2026-04-08 Riken Method for maturing cardiomyocytes, and method for producing matured cardiomyocytes
JPWO2024248157A1 (enExample) 2023-05-31 2024-12-05

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
DE19910044A1 (de) * 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
US20040199935A1 (en) * 1999-06-30 2004-10-07 Chapman Karen B. Cytoplasmic transfer to de-differentiate recipient cells
WO2001096532A2 (en) * 2000-06-15 2001-12-20 Tanja Dominko Method of generating pluripotent mammalian cells by fusion of a cytoplast fragment with a karyoplast
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20020136709A1 (en) * 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
ATE488583T1 (de) * 2001-02-21 2010-12-15 Wistar Inst Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält
WO2003018780A1 (en) * 2001-08-27 2003-03-06 Advanced Cell Technology, Inc. De-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
JP2004248505A (ja) 2001-09-21 2004-09-09 Norio Nakatsuji 移植抗原の一部または全てを欠除したｅｓ細胞由来の未分化な体細胞融合細胞およびその製造
ITMI20012110A1 (it) 2001-10-12 2003-04-12 Keryos Spa Vettori multi-cistronici utilizzabili in protocolli di trsferimento genico
WO2003056019A1 (en) 2001-12-24 2003-07-10 Es Cell International Pte Ltd Method of transducing es cells
GB0202149D0 (en) 2002-01-30 2002-03-20 Univ Edinburgh Pluripotency determining factors and uses thereof
GB0206357D0 (en) 2002-03-18 2002-05-01 Univ Bath Cells
BR122017016940B8 (pt) * 2002-04-25 2021-07-27 Transkaryotic Therapies Inc método para preparação de uma composição farmacêutica compreendendo alfa-galactosidase a
EP1572984B8 (en) * 2002-12-16 2016-06-01 Technion Research & Development Foundation Ltd. Feeder-free, xeno-free culture system for human embryonic stem cells
CA2515108A1 (en) 2003-02-07 2004-08-26 Wisconsin Alumni Research Foundation Directed genetic modifications of human stem cells
US7682828B2 (en) 2003-11-26 2010-03-23 Whitehead Institute For Biomedical Research Methods for reprogramming somatic cells
US7638331B2 (en) * 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
JP2007528226A (ja) * 2004-03-10 2007-10-11 リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア 胚幹細胞の増殖用組成物および方法
KR100484653B1 (ko) 2004-05-06 2005-04-20 주식회사 대웅 원핵세포에서 활성형의 가용성 단백질을 제조하는 방법 및 이를 위한 폴리시스트론 벡터
US7465580B2 (en) 2004-05-19 2008-12-16 Wisconsin Alumni Research Foundation Non-cytotoxic oriP replicon
EP1756094A1 (en) 2004-06-18 2007-02-28 Glaxo Group Limited 3-cycloalkylbenzazepines as histamine h3 antagonists
US7566548B2 (en) * 2004-08-13 2009-07-28 University Of Massachusetts Methods for identifying therapeutic agents and for treating disease
CA2659945C (en) * 2005-08-03 2014-12-16 Advanced Cell Technology, Inc. Improved methods of reprogramming animal somatic cells
US20080199849A1 (en) 2005-09-02 2008-08-21 Agency For Science, Technology And Research Method of Deriving Progenitor Cell Line
US20070087437A1 (en) 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
CN101864392B (zh) * 2005-12-13 2016-03-23 国立大学法人京都大学 核重新编程因子
US8278104B2 (en) 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
JP4803584B2 (ja) 2006-02-08 2011-10-26 独立行政法人産業技術総合研究所 脂質生産性の高い形質転換微生物
TW200817512A (en) 2006-07-07 2008-04-16 Kirin Pharma Kk Human artificial chromosome (hac) vector, and human cell pharmaceutical comprising human artificial chromosome (hac) vector
EP2054079A4 (en) 2006-07-19 2009-12-23 Univ Florida COMPOSITIONS FOR CELL REPROGRAMMING AND USES THEREOF
JP2008067693A (ja) 2006-08-15 2008-03-27 Ishihara Sangyo Kaisha Ltd 微生物変異体の新規利用方法
EP2053128A4 (en) 2006-08-15 2010-05-05 Ishihara Sangyo Kaisha INNOVATIVE METHOD OF USING MICROBIAL MUTANT
JP2010500047A (ja) 2006-08-15 2010-01-07 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間葉系幹細胞馴化培地
WO2008033469A1 (en) 2006-09-15 2008-03-20 Children's Medical Center Corporation Methods for producing embryonic stem cells from parthenogenetic embryos
EP3399025B1 (en) 2007-03-23 2025-05-07 Wisconsin Alumni Research Foundation Somatic cell reprogramming
PT2164993T (pt) 2007-05-29 2017-01-12 Reid Christopher B Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
EP2198011B1 (en) 2007-08-31 2016-06-08 Whitehead Institute for Biomedical Research Wnt pathway stimulation in reprogramming somatic cells
US7615374B2 (en) 2007-09-25 2009-11-10 Wisconsin Alumni Research Foundation Generation of clonal mesenchymal progenitors and mesenchymal stem cell lines under serum-free conditions
US20110236971A2 (en) 2007-09-25 2011-09-29 Maksym Vodyanyk Generation of Clonal Mesenchymal Progenitors and Mesenchymal Stem Cell Lines Under Serum-Free Conditions
WO2009058712A1 (en) * 2007-10-29 2009-05-07 Trustees Of Dartmouth College Toxoplasma gondii mutant with enhanced homologous recombination and uses thereof
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method
US20110151447A1 (en) * 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
US9005966B2 (en) 2007-11-19 2015-04-14 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
WO2009091543A1 (en) 2008-01-14 2009-07-23 Lindner Scott E An efficient orip/ebna-1 plasmid vector
WO2009092042A1 (en) 2008-01-18 2009-07-23 Nevada Cancer Institute Reprogramming of differentiated progenitor or somatic cells using homologous recombination
US20110014164A1 (en) * 2008-02-15 2011-01-20 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
CN101855350B (zh) 2008-05-02 2014-12-31 国立大学法人京都大学 核重编程序方法
CA2726990C (en) 2008-06-04 2020-09-08 Cellular Dynamics International, Inc. Methods for the production of ips cells using extra-chromosomal vectors
WO2010012077A1 (en) 2008-07-28 2010-02-04 Mount Sinai Hospital Compositions, methods and kits for reprogramming somatic cells
JP2012500005A (ja) 2008-08-12 2012-01-05 セルラー ダイナミクス インターナショナル， インコーポレイテッド ｉＰＳ細胞を生成するための方法
WO2010028019A2 (en) 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
CN102239249A (zh) 2008-10-24 2011-11-09 威斯康星校友研究基金会 通过非病毒重编程获得的多潜能干细胞

Also Published As

Publication number Publication date
JP2010521990A (ja) 2010-07-01
SG193652A1 (en) 2013-10-30
US20200239840A1 (en) 2020-07-30
CA2684242A1 (en) 2008-10-02
IL200982A0 (en) 2010-05-17
JP2024038501A (ja) 2024-03-19
JP6788329B2 (ja) 2020-11-25
SG193653A1 (en) 2013-10-30
DK3399025T3 (da) 2025-06-16
AU2008231020A1 (en) 2008-10-02
WO2008118820A2 (en) 2008-10-02
US20140057355A1 (en) 2014-02-27
US20190106675A1 (en) 2019-04-11
EP3399025B1 (en) 2025-05-07
EP2137296A2 (en) 2009-12-30
US11898162B2 (en) 2024-02-13
WO2008118820A3 (en) 2008-11-20
US20130210138A1 (en) 2013-08-15
US20240271087A1 (en) 2024-08-15
JP6924732B2 (ja) 2021-08-25
JP2018183183A (ja) 2018-11-22
EP3399025A1 (en) 2018-11-07
US10106772B2 (en) 2018-10-23
US8183038B2 (en) 2012-05-22
KR101516833B1 (ko) 2015-05-07
IL200982A (en) 2013-03-24
US20080233610A1 (en) 2008-09-25
CN101743306A (zh) 2010-06-16
JP2021176331A (ja) 2021-11-11
JP5813321B2 (ja) 2015-11-17
US20110028537A1 (en) 2011-02-03
US9499786B2 (en) 2016-11-22
JP2018183182A (ja) 2018-11-22
US8440461B2 (en) 2013-05-14
KR20090126303A (ko) 2009-12-08
AU2008231020B2 (en) 2013-09-05
JP2015165810A (ja) 2015-09-24

Similar Documents

Publication Publication Date Title
US20240271087A1 (en) Somatic Cell Reprogramming
EP2476750A1 (en) Somatic cell reprogramming
US10221396B2 (en) Reprogramming T cells and hematopoietic cells
US20190330654A1 (en) Pluripotent stem cells obtained by non-viral reprogramming
CN102190731B (zh) 用人工转录因子诱导产生多能干细胞
AU2008360135A1 (en) Efficient method for establishing induced pluripotent stem cells
WO2010042800A1 (en) Methods of reprogramming somatic cells and methods of use for such cells
HK1247640A1 (zh) 高品质ips细胞的制造方法
AU2015200413B2 (en) Reprogramming t cells and hematopoietic cells
WO2010131747A1 (ja) ウイルス産生細胞
AU2016200360B2 (en) Somatic cell reprogramming
AU2013267048B2 (en) Somatic cell reprogramming
HK1172057A (en) Somatic cell reprogramming

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130318

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250312

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250312

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250312

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260309

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260309